Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 29;50(1):11–25. doi: 10.1007/s15010-021-01664-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Graphical representation of the longevity and magnitude of the nAb antibody response to coronaviruses. a Shows trends in antibody kinetics to SARS-CoV, MERS-CoV and HCoVs, highlighting the relatively rapid waning of HCoV nAbs as well as higher titres generated in severe SARS-CoV/MERS-CoV infection [28–32, 34–38, 40–42, 44, 52]. The dotted line indicates a lack of serological data for common cold coronavirus infections in individuals naïve to the infection. b Compares antibody titre trends in severe and mild SARS-CoV-2 and their waning over time, highlighting the higher titres generated in severe infection [56–58, 60, 62–64]. Neither graph drawn to scale. SARS-CoV severe acute respiratory syndrome coronavirus, MERS-CoV Middle East respiratory syndrome coronavirus, HCoV human coronavirus